Intellia Therapeutics, Inc. (NTLA) stock forecast and price target
Price $9.70 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($9.70)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-3.27 | +14.2% | $43M |
| Next fiscal year ends December 31, 2027 | $-2.70 | +17.5% | $119M |
| Next quarter ends December 31, 2026 | $-0.78 | +6.3% | $14M |
| Quarter after ends March 31, 2027 | $-0.83 | −2.3% | $11M |
Consensus of the analysts covering Intellia Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 6 lowered.
Frequently asked questions
What is the Intellia Therapeutics stock price target?
The average 12-month target from 18 analysts is $22.78, 134.8% above the current price of $9.70 Targets range from $8.00 to $61.00.
Is Intellia Therapeutics a buy according to analysts?
The consensus rating is “Buy” (1 strong buy, 9 buy, 6 hold, 2 sell, 2 strong sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Intellia Therapeutics expected to earn?
Analysts expect EPS of $-3.27 for the fiscal year ending December 31, 2026 and $-2.70 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.